case_images: PMC10505928_01
case_images: (A) Changes in various cerebrospinal fluid indicators before and after zanubrutinib discontinuation in the patient (B-C) Brain MRI of the patient before zanubrutinib discontinuation. (B) T1 enhancement; (C) T2. (D-E) Brain MRI after the patient stopped using zanubrutinib for 4 months. (D) T1 enhancement; (E) T2. (F) Detailed time course of the patient's clinical course and therapeutic regimen.
case_images: fphar-14-1242491-g001.jpg
case_images: PMC10505928_01_fphar-14-1242491-g001.jpg
case_images: F1
case_images: The cell count, protein, and glucose were 300 x 106/L (normal range: 0-10 x 106/L), 690 mg/dL (normal range: 15-45 mg/dL), and 42.84 mg/dL (normal range: 45-79.2 mg/dL), respectively (Figure 1A). Brain magnetic resonance imaging (MRI) enhanced scan illustrated meninges thickening, cistern narrowing, third ventricle and bilateral lateral ventricle enlargement and hydrocephalus, and CSF exudation (Figures 1B, C). The cell count and protein by the CSF analysis significantly decreased (Figure 1A). Enhanced brain MRI scanning revealed that the enhancement degree of intracranial pia mater and hydrocephalus was reduced (Figures 1D, E). The therapeutic course is summarized in Figure 1F.